RecruitingPhase 1Phase 2NCT07285694
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy of AB-3028 in Patients With Castration Resistant Prostate Cancer (CRPC)
Sponsor
Arsenal Biosciences, Inc.
Enrollment
190 participants
Start Date
Jan 9, 2026
Study Type
INTERVENTIONAL
Summary
This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
Eligibility
Sex: MALEMin Age: 18 Years
Inclusion Criteria7
- At least 18 years of age at time of signing informed consent form.
- Histologically confirmed adenocarcinoma of the prostate, meeting all of the following criteria:
- • Documented progressive metastatic castration-resistant prostate cancer (mCRPC) based on PCWG3 criteria.
- Prior prostate cancer treatment with at least 1 novel androgen receptor pathway inhibitor (ARPI) therapy.
- • PSMA+ by PSMA PET.
- Measurable disease by RECIST 1.1 criteria, or evaluable disease via measurable PSA (≥ 1 ng/mL) per PCWG3 criteria.
- Adequate organ functions.
Exclusion Criteria3
- Any prior systemic therapy for CRPC within 14 days prior to scheduled protocol required leukapheresis.
- Central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression.
- Unwillingness to participate in an extended safety monitoring period.
Interventions
BIOLOGICALAB-3028
autologous T cell therapy
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07285694